Lilly, Daiichi launch prasugrel in U.K.

Justine Varieur Cadet | | Cardiovascular Business | Interventional Cardiology
Eli Lilly and Daiichi Sankyo have launched their new heart drug prasugrel (Efient) in the U.K., following its authorization by the European Medicines Agency (EMEA).

Prasugrel is indicated for patients with acute coronary syndrome, who have unstable angina or have had a heart attack. The approval of prasugrel is based upon data from several trials including TRITON-TIMI 38, a global head-to-head superiority trial involving 13,608 patients worldwide, when compared to clopidogrel (Plavix), according to the Indianapolis-based Lilly and the Tokyo-based Daiichi.

Prasugrel is the first new oral antiplatelet to be licensed in the U.K. for more than a decade.

Justine Varieur Cadet

Related Content

Clopidogrel vs. aspirin: Tracking the chronic maintenance period after PCI for different risk groups
Off-label TAVR for native aortic regurgitation linked to worse outcomes
Medtronic TAVR valves at heart of key studies presented during PCR London Valves 2024
Shockwave Medical’s IVL technology still safe, effective in patients with calcified nodules
Prosthesis-patient mismatch after TAVR: 5 key findings related to patients with small annuli
First patients treated with Abbott’s new balloon-expandable TAVR valve

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."